Authors
Budul N.A. 1, Terpigorev S.A.2, Komerdus I.V.1, Mikhaylova D.S.1, Ilovayskaya I.A.1
1 Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russia
2 Pirogov National Medical and Surgical Center, Moscow, Russia
Abstract
Background: Pulmonary sarcoidosis is a rare disease where glucocorticoid therapy is the first-line treatment.
Objective: To assess the clinical and metabolic changes occurring within the first 3 months of methylprednisolone therapy in patients with pulmonary sarcoidosis.
Materials and Methods: A single-center prospective observational study was conducted involving 23 patients with pulmonary sarcoidosis. Methylprednisolone was prescribed at an initial dose of 12–24 mg/day for 1 month, followed by 8 mg/day during the second and third months of treatment. Patients were assessed initially and after 1 and 3 months of methylprednisolone therapy. Clinical manifestations of the systemic effects of glucocorticoids, anthropometric parameters, blood pressure, and lipid, carbohydrate, and electrolyte metabolism parameters were evaluated.
Results: after the first month of therapy weight gain in the most of the patients, a significant increase in total cholesterol levels (from 6.0 [5.5; 6.8] mmol/l at baseline to 6.9 [5.5; 7.4] mmol/l, p = 0,027), frequency of hypokalemia increased (from 17.4% at baseline to 47.8% p = 0,03) were noted, and these changes persisted till the third month of therapy. Also new cases of early carbohydrate metabolism disturbances were found after the first and the third month of the therapy. The frequency of “moon face”, enhanced appetite, and irritability/emotional lability were dose depended: increased significantly after 1 month of therapy and regressed by the third month of methylprednisolone therapy.
Conclusion: The most clinically significant changes were weight gain, alterations in lipid and carbohydrate metabolism, and an increased frequency of hypokalemia, all of which developed as early as 1 month after initiation of methylprednisolone therapy and did not regress after methylprednisolone dose reduction.
Keywords: pulmonary sarcoidosis, glucocorticoids, methylprednisolone.
References
1. Chuchalin AG, Avdeev SN, Vizel AA, et al. Sarcoidosis. (Clinical guidelines. Short version). Journal of Respiratory Medicine. 2026; 2(1): 28-40. (In Russ.) doi: 10.17116/respmed2026201128.
2. Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists. Pulm Ther. 2021; 7(2): 325-344. doi: 10.1007/s41030-021-00160-x.
3. Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society. 2022. doi: 10.1183/ 2312508X.10031020.
4. Laugesen K, et.al. Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. European journal of endocrinology. 2019; 3(181): 267-273.
5. Bénard-Laribière A, et.al. Prevalence and prescription patterns of oral glucocorticoids in adults: A retrospective cross-sectional and cohort analysis in France. BMJ Open. 2017; 7(7): 1-7.
6. Buchman AL. Side effects of corticosteroid therapy. Journal of clinical gastroenterology. 2001; 4(33): 289-294.
7. Cristante J, Chabre O. Factitious, or iatrogenic but unexpected Cushing’s syndrome. Annales d’Endocrinologie. 2023; 3(84): 370-372.
8. Esen I, Arends S, Dalsgaard Nielsen B, et.al. Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort. RMD Open. 2023; 9(1): e002640. doi: 10.1136/rmdopen-2022-002640.
9. DeMaria AN, DeMaria EJ, Amsterdam EA, et al. Effects of short-term high-dose prednisone on serum lipids in healthy volunteers. J Clin Pharmacol. 2012; 52(7): 1065-1072. doi: 10.1177/0091270011415412.
10. Han TS, Walker BR, Arlt W, et al. Short-term glucocorticoid use and the risk of adverse events: a population-based cohort study. J Clin Endocrinol Metab. 2017; 102(8): 2935-2943. doi: 10.1210/jc.2017-00693.
11. Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annu Rev Physiol. 2022 Feb 10;84:585-610. doi: 10.1146/annurev-physiol-060821-013950.
12. Ariza-Andraca CR, Barile-Fabris LA, Fraga-Mouret A, et al. Risk factors for steroid-induced abnormal glucose tolerance in patients with rheumatic diseases. Rev Invest Clin. 1998; 50(5): 413-418.
13. Nakamura H, Fujieda Y, Nakamura A, Atsumi T. How should rheumatologists manage glucocorticoid-induced hyperglycemia? Mod Rheumatol. 2021; 31(3): 519-528. doi: 10.1080/14397595.2020.1823060.
14. Shah P, Kalra S, Yadav Y, et.al. Management of Glucocorticoid-Induced Hyperglycemia. Diabetes Metab Syndr Obes. 2022; 15: 1577-1588. doi: 10.2147/DMSO.S330253.
15. Riccardo P, Giorgio C, David WR, Jeremy WT. Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad? Endocrine Reviews. 2023; 44(6): 975-1011. doi: 10.1210/endrev/bnad016.
16. Fardet L, Flahault A, Kettaneh A, et.al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007; 157(1): 142-8. doi: 10.1111/j.1365-2133.2007.07950.x.


